Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.25m15794 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Briana M Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona. Hauptthemen laut MEDLINE: Schizophrenia, Cognitive Dysfunction, Cost of Illness, Health Expenditures.
Abstract (Originalsprache)
Objectives
To estimate prevalence and impact of cognitive impairments in schizophrenia in the US.
Methods
Retrospective analyses of the Medical Expenditure Panel Survey (1997-2021) were conducted to identify adults living with schizophrenia and cognitive impairments. Cognitive limitations (CL; 1997-2021) were defined as interference with daily activities, confusion/memory loss, problems making decisions, or requiring supervision for safety. Cognitive difficulties (CD; 2013-2021) were defined as difficulty in concentration/memory/decision-making. Descriptive analyses covered demographic, clinical, and socioeconomic characteristics, health care resource utilization (HCRU), humanistic, and indirect burdens. Multivariable regression analyses were conducted for hospitalizations, emergency department (ED) visits, and total costs. Sampling weights were applied.
Results
Among 661,243 weighted adults living with schizophrenia (mean age: 45.6 years; male: 56.7%), 57.7% reported CL, and 53.8% reported CD. Compared to no CL, CL was associated with lower education (no degree: +2.2%) and annual income (-$4,332) and higher Charlson Comorbidity Index (0.89 vs 0.55) and HCRU. Total health care costs were higher for CL ($18,478 vs $11,689), demonstrating greater economic burden. Individuals reporting CL reported more limitations in activities of daily living (+13.3%) and lower health utilities scores with higher percentage of poor perceived health (+10.1%), indicating higher humanistic burden. For indirect burden, CL was associated with higher unemployment (+15.3%) (all P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona.
- BluePath Solutions, Los Angeles, California.
- Corresponding Author: Briana M. Choi, PharmD, PhD, Pharmaceutical Sciences, College of Pharmacy, University of Arizona, 1703 E Mabel St, Tucson, AZ 85721 (bchoi1@arizona.edu).
- Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, Connecticut.
- Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York.
- Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Hempstead, New York.
Zitieren
APA
Choi, B. M., Singh, T., Nili, M., Lam, C., Xiang, P., McGarvey, N., & Correll, C. U. (2025). Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m15794
Vancouver
Choi BM, Singh T, Nili M, Lam C, Xiang P, McGarvey N, et al. Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.25m15794
BibTeX
@article{Choi2025,
author = {Choi, Briana M and Singh, Tavneet and Nili, Mona and Lam, Cindy and Xiang, Pin and McGarvey, November and Correll, Christoph U},
title = {Understanding the Characteristics and Burden of Cognitive Impairments in Schizophrenia in the US},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.25m15794}
}
EUVIMED